Key result
This review discusses new evidence for the use of the diuretic acetazolamide as an add-on therapy for decongestion in acute heart failure.
Why the study?
Loop diuretic therapy alone may not provide adequate decongestion in acute heart failure due to diuretic resistance, prompting evaluation of alternative add-on therapies such as acetazolamide.
Does acetazolamide improve outcomes in patients with acute heart failure?
Does acetazolamide improve outcomes in patients with acute heart failure?
This review discusses emerging evidence for the use of acetazolamide as an add-on diuretic therapy for decongestion in acute heart failure.
Answers are grounded in this paper and cite their sources.
Acetazolamide may be considered over thiazides for residual congestion; leaves open head-to-head trials before any practice change.
The primary treatment for acute heart failure includes the use of intravenous loop diuretics to reduce congestion. Successful decongestion at the time of hospital discharge improves mortality and prevents rehospitalization in these patients. Loop diuretic therapy alone may not be enough for adequate decongestion, especially as diuretic resistance becomes more common. Other therapies include the addition of thiazide diuretics, though increasing evidence might suggest a better alternative to add-on therapy. In this review, we will discuss the new evidence for the use of the diuretic acetazolamide in acute heart failure.
No takes yet. Share an insight, caveat, or question.
Veasaw et al. (2023) conducted a review in Acute heart failure. Acetazolamide was evaluated. This review discusses new evidence for the use of the diuretic acetazolamide as an add-on therapy for decongestion in acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: